Aska Pharmaceuticals Of Japan Enhances Pipeline And Plans To Enter Generics Market
This article was originally published in PharmAsia News
Aska Pharmaceuticals President Takashi Yamaguchi expects menopausal symptoms drug Menoaid Patch will be NHI price-listed within the year. With an estimated ¥2 billion in potential sales, Aska will establish a team to prepare for next year's market launch. Aska has eight items in its pipeline, including Tavocept (dimensa), a neuropathy drug to reduce side effects of taking cancer drugs, that has shown promising results in Phase III trials in Japan. Yamaguchi also disclosed that the company plans to enter generics field with a focus on internal medicine, urology, OBGYN and otology drugs, Aska sets a ¥10 billion sales goal by fiscal year 2010. (Click here for more - Japanese language
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.